CoA Therapeutics, Inc., a BridgeBio company
CoA Therapeutics is dedicated to developing therapies targeting Coenzyme A (CoA) for patients with genetic disorders such as PKAN, organic acidurias, and other diseases related to CoA sequestration. Founded in 2018, the company leverages scientific advances in the CoA pathway to create novel treatments for rare and difficult-to-treat genetic disorders.
Industries
Nr. of Employees
small (1-50)
CoA Therapeutics, Inc., a BridgeBio company
1800 Owens Street, Suite C-1200, San Francisco, CA 94158
Products
Preclinical and clinical-stage small-molecule programs targeting CoA biosynthesis
Therapeutic development programs focused on small molecules that bind pantothenate kinase isoforms to prevent feedback inhibition and increase CoA levels, intended to treat PKAN and organic acidurias.
Preclinical and clinical-stage small-molecule programs targeting CoA biosynthesis
Therapeutic development programs focused on small molecules that bind pantothenate kinase isoforms to prevent feedback inhibition and increase CoA levels, intended to treat PKAN and organic acidurias.
Services
End-to-end internal development of small-molecule therapeutic candidates that modulate CoA biosynthesis for treatment of PKAN and organic acidurias.
End-to-end internal development of small-molecule therapeutic candidates that modulate CoA biosynthesis for treatment of PKAN and organic acidurias.
Expertise Areas
- CoA pathway biology and modulation
- Rare genetic disease drug development
- Pantothenate kinase-associated neurodegeneration (PKAN)
- Organic acidurias (propionic and methylmalonic acidemias)
Key Technologies
- Small-molecule therapeutics
- Enzyme-targeted drug design (pantothenate kinase modulation)
- Metabolic pathway analysis
- Biochemical assays for CoA and thioesters
News & Updates
BridgeBio Pharma announces the dosing of the first patient in a Phase 1 trial of BBP-671, a potential treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA).
An article discussing biomarkers relevant for drug development in PA and MMA.
Research findings on new treatment strategies for PA.
A press release about data demonstrating CoA Therapeutics’ potential to treat PKAN.
Announcement of the launch of CoA Therapeutics by BridgeBio Pharma.
BridgeBio Pharma announces the dosing of the first patient in a Phase 1 trial of BBP-671, a potential treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA).
An article discussing biomarkers relevant for drug development in PA and MMA.
Research findings on new treatment strategies for PA.
A press release about data demonstrating CoA Therapeutics’ potential to treat PKAN.
Announcement of the launch of CoA Therapeutics by BridgeBio Pharma.